Global Biologics for Obstructive Airway Diseases Supply, Demand and Key Producers, 2026-2032
The global Biologics for Obstructive Airway Diseases market size is expected to reach $ 22862 million by 2032, rising at a market growth of 8.1% CAGR during the forecast period (2026-2032).
Biologics for Obstructive Airway Diseases refer to biologic medicines produced using biotechnology that exert therapeutic effects by specifically modulating targets or signaling pathways associated with airway inflammation, allergic responses, and immune reactions, and that are classified under R03, Drugs for Obstructive Airway Diseases, of the World Health Organization Anatomical Therapeutic Chemical Classification System. These medicines primarily act by targeting key inflammatory mediators or receptors, including immunoglobulin E, interleukin-5, the interleukin-5 receptor, and thymic stromal lymphopoietin, thereby reducing airway inflammation, eosinophil activation, and allergic responses. They are mainly used to reduce disease exacerbations, improve lung function, and enhance disease control in severe asthma, chronic obstructive pulmonary disease, and other obstructive airway diseases covered by relevant approved indications.
For the purposes of this report, a product is included only when it meets both criteria: it is classified under ATC R03 and it qualifies as a biologic medicine. Inhaled corticosteroids, bronchodilators, leukotriene receptor antagonists, and other small-molecule medicines within R03 are excluded. Biologic medicines outside R03 are also excluded even if they are used to treat asthma, chronic obstructive pulmonary disease, or other respiratory diseases. Both originator biologics and biosimilars are included under their corresponding active substances and ATC classifications.
Biologics for obstructive airway diseases are biologic medicines produced using biotechnology and classified under R03, Drugs for Obstructive Airway Diseases, of the World Health Organization Anatomical Therapeutic Chemical Classification System. These medicines act primarily by specifically targeting key molecules involved in airway inflammation, allergic responses, and immune regulation. Current major targets include immunoglobulin E, interleukin-5, the interleukin-5 receptor, and thymic stromal lymphopoietin. They are mainly used for severe asthma, selected forms of chronic obstructive pulmonary disease, and other obstructive airway diseases covered by relevant approved indications. The industry excludes inhaled corticosteroids, bronchodilators, and other small-molecule drugs within R03, as well as respiratory biologics whose ATC classifications fall outside R03.
By product structure, monoclonal antibodies account for the dominant share of biologics for obstructive airway diseases. Representative active substances include omalizumab, mepolizumab, reslizumab, benralizumab, tezepelumab, and depemokimab. These products achieve differentiated therapeutic effects by inhibiting immunoglobulin E, eosinophil-related pathways, or upstream inflammatory mediators. Immunoglobulin E-targeted therapies have been commercialized for a relatively long period and are entering a market environment in which originator products and biosimilars coexist. Interleukin-5 and interleukin-5 receptor therapies primarily target severe eosinophilic asthma, while thymic stromal lymphopoietin-targeted therapies act further upstream in the inflammatory cascade and may therefore cover a broader patient population.
By therapeutic application, severe asthma currently represents the principal area of use. Biologics are generally used in patients whose disease remains inadequately controlled with conventional inhaled therapies and who exhibit identifiable allergic, eosinophilic, or other inflammatory phenotypes. As biomarker testing and patient stratification improve, clinical management is shifting from conventional symptom control toward precision treatment based on disease phenotype and underlying inflammatory mechanisms. At the same time, selected biologics are expanding into chronic obstructive pulmonary disease, particularly among patients with eosinophilic inflammation, creating an additional source of industry growth.
Subcutaneous injection is currently the dominant route of administration. Several products are available in prefilled syringes or autoinjectors, allowing treatment to gradually shift from hospitals and specialty clinics toward homecare settings. A limited number of products continue to be administered by intravenous infusion, primarily in hospitals or specialized healthcare facilities. Longer dosing intervals, more convenient delivery devices, and improved self-administration capabilities are becoming important competitive attributes for next-generation therapies, helping improve long-term adherence and reduce the treatment burden on patients.
The upstream supply chain primarily includes cell lines, culture media, single-use bioprocess consumables, bioreactors, filtration systems, chromatography resins, buffer materials, syringes, and other sterile packaging components. Midstream activities include cell culture, harvest, purification, viral clearance, drug substance preparation, formulation, aseptic filling, quality testing, and batch release. Downstream access is primarily through hospitals, respiratory and allergy specialty clinics, specialty pharmacies, and homecare settings. Because these products require stringent control of protein structure, purity, biological activity, aggregation, impurities, and sterility, manufacturing is subject to demanding quality management and batch consistency requirements.
From a manufacturing perspective, most products are produced using mammalian cell expression systems. Commercial manufacturing generally involves cell culture in bioreactors followed by multi-stage filtration and chromatography purification. Individual bioreactors in commercial production lines commonly range from approximately 2,000 to 20,000 liters, while large manufacturing facilities typically operate multiple bioreactors together with associated downstream purification systems. There is no single standardized annual capacity per production line, as effective output depends on antibody titer, culture cycle, batch frequency, bioreactor configuration, purification yield, and facility utilization. Large stainless-steel systems provide significant economies of scale for mature high-volume antibody products, whereas single-use systems offer greater flexibility for multiproduct and smaller-batch manufacturing.
Major cost components include culture media and single-use consumables, chromatography resins, facility depreciation, labor, quality testing, utilities, fill-finish operations, packaging, and cold-chain logistics. Unit manufacturing costs can decline materially as production scale and antibody titers increase, giving mature commercial products substantial economies of scale. Innovative originator biologics typically benefit from premium pricing and strong patent protection, and gross margins for mature products can generally reach approximately 60% to 85%. Biosimilars typically generate lower gross margins because of stronger price competition and distribution costs, although manufacturers with efficient large-scale production can still maintain attractive profitability.
The industry is characterized by high research and development, manufacturing, and regulatory barriers. Companies must not only complete complex clinical development and indication-specific validation but also establish biologics manufacturing systems that comply with good manufacturing practice requirements and consistently maintain product quality, aseptic control, and pharmacovigilance standards. For biosimilars, manufacturers must demonstrate a high degree of structural and functional similarity to the reference product and satisfy regulatory requirements concerning quality, clinical comparability, and immunogenicity. Companies with established cell culture, purification, and analytical quality platforms therefore possess significant competitive advantages.
The global competitive landscape remains relatively concentrated, with major originator products controlled by a limited number of large multinational pharmaceutical companies. These companies maintain their positions through extensive clinical evidence, indication expansion, brand recognition, and global commercialization networks. As patents for earlier products expire, mature molecules such as omalizumab are entering biosimilar competition, while biologics manufacturers from South Korea, China, and other regions are increasingly participating in the market. In China, the market remains in a stage of domestic substitution and increasing biologic penetration, with local companies initially targeting mature molecules such as omalizumab while expanding large-scale antibody manufacturing and commercialization capabilities.
Distribution and end-use patterns are highly specialized. Patients are commonly selected using serum immunoglobulin E levels, peripheral blood eosinophil counts, allergen testing, and other clinical indicators, making product use highly dependent on respiratory specialists, allergists, and other specialized physicians. As prefilled formulations, self-injection products, and remote patient-management models become more widely adopted, the proportion of home-based treatment is expected to increase. However, initial administration, response assessment, and monitoring for serious adverse events are expected to remain concentrated in professional healthcare settings.
Future industry growth will be driven primarily by higher penetration of biologic therapies in severe asthma, expansion into chronic obstructive pulmonary disease, development of novel inflammatory targets, biomarker-driven precision patient stratification, and improved patient access in emerging markets. At the same time, biosimilar competition for mature products such as omalizumab will continue to exert downward pressure on pricing, gradually shifting market growth from price-driven expansion toward growth in treated patient populations and new indications. Competition is therefore expected to move beyond efficacy at a single target toward a broader combination of patient coverage, lower dosing frequency, more convenient administration, long-term safety, and overall cost effectiveness.
This report is a detailed and comprehensive analysis of the world market for Biologics for Obstructive Airway Diseases, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Biologics for Obstructive Airway Diseases that contribute to its increasing demand across many markets.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Biologics for Obstructive Airway Diseases market
2. What is the demand of the global Biologics for Obstructive Airway Diseases market?
3. What is the year over year growth of the global Biologics for Obstructive Airway Diseases market?
4. What is the total value of the global Biologics for Obstructive Airway Diseases market?
5. Who are the Major Players in the global Biologics for Obstructive Airway Diseases market?
6. What are the growth factors driving the market demand?
Biologics for Obstructive Airway Diseases refer to biologic medicines produced using biotechnology that exert therapeutic effects by specifically modulating targets or signaling pathways associated with airway inflammation, allergic responses, and immune reactions, and that are classified under R03, Drugs for Obstructive Airway Diseases, of the World Health Organization Anatomical Therapeutic Chemical Classification System. These medicines primarily act by targeting key inflammatory mediators or receptors, including immunoglobulin E, interleukin-5, the interleukin-5 receptor, and thymic stromal lymphopoietin, thereby reducing airway inflammation, eosinophil activation, and allergic responses. They are mainly used to reduce disease exacerbations, improve lung function, and enhance disease control in severe asthma, chronic obstructive pulmonary disease, and other obstructive airway diseases covered by relevant approved indications.
For the purposes of this report, a product is included only when it meets both criteria: it is classified under ATC R03 and it qualifies as a biologic medicine. Inhaled corticosteroids, bronchodilators, leukotriene receptor antagonists, and other small-molecule medicines within R03 are excluded. Biologic medicines outside R03 are also excluded even if they are used to treat asthma, chronic obstructive pulmonary disease, or other respiratory diseases. Both originator biologics and biosimilars are included under their corresponding active substances and ATC classifications.
Biologics for obstructive airway diseases are biologic medicines produced using biotechnology and classified under R03, Drugs for Obstructive Airway Diseases, of the World Health Organization Anatomical Therapeutic Chemical Classification System. These medicines act primarily by specifically targeting key molecules involved in airway inflammation, allergic responses, and immune regulation. Current major targets include immunoglobulin E, interleukin-5, the interleukin-5 receptor, and thymic stromal lymphopoietin. They are mainly used for severe asthma, selected forms of chronic obstructive pulmonary disease, and other obstructive airway diseases covered by relevant approved indications. The industry excludes inhaled corticosteroids, bronchodilators, and other small-molecule drugs within R03, as well as respiratory biologics whose ATC classifications fall outside R03.
By product structure, monoclonal antibodies account for the dominant share of biologics for obstructive airway diseases. Representative active substances include omalizumab, mepolizumab, reslizumab, benralizumab, tezepelumab, and depemokimab. These products achieve differentiated therapeutic effects by inhibiting immunoglobulin E, eosinophil-related pathways, or upstream inflammatory mediators. Immunoglobulin E-targeted therapies have been commercialized for a relatively long period and are entering a market environment in which originator products and biosimilars coexist. Interleukin-5 and interleukin-5 receptor therapies primarily target severe eosinophilic asthma, while thymic stromal lymphopoietin-targeted therapies act further upstream in the inflammatory cascade and may therefore cover a broader patient population.
By therapeutic application, severe asthma currently represents the principal area of use. Biologics are generally used in patients whose disease remains inadequately controlled with conventional inhaled therapies and who exhibit identifiable allergic, eosinophilic, or other inflammatory phenotypes. As biomarker testing and patient stratification improve, clinical management is shifting from conventional symptom control toward precision treatment based on disease phenotype and underlying inflammatory mechanisms. At the same time, selected biologics are expanding into chronic obstructive pulmonary disease, particularly among patients with eosinophilic inflammation, creating an additional source of industry growth.
Subcutaneous injection is currently the dominant route of administration. Several products are available in prefilled syringes or autoinjectors, allowing treatment to gradually shift from hospitals and specialty clinics toward homecare settings. A limited number of products continue to be administered by intravenous infusion, primarily in hospitals or specialized healthcare facilities. Longer dosing intervals, more convenient delivery devices, and improved self-administration capabilities are becoming important competitive attributes for next-generation therapies, helping improve long-term adherence and reduce the treatment burden on patients.
The upstream supply chain primarily includes cell lines, culture media, single-use bioprocess consumables, bioreactors, filtration systems, chromatography resins, buffer materials, syringes, and other sterile packaging components. Midstream activities include cell culture, harvest, purification, viral clearance, drug substance preparation, formulation, aseptic filling, quality testing, and batch release. Downstream access is primarily through hospitals, respiratory and allergy specialty clinics, specialty pharmacies, and homecare settings. Because these products require stringent control of protein structure, purity, biological activity, aggregation, impurities, and sterility, manufacturing is subject to demanding quality management and batch consistency requirements.
From a manufacturing perspective, most products are produced using mammalian cell expression systems. Commercial manufacturing generally involves cell culture in bioreactors followed by multi-stage filtration and chromatography purification. Individual bioreactors in commercial production lines commonly range from approximately 2,000 to 20,000 liters, while large manufacturing facilities typically operate multiple bioreactors together with associated downstream purification systems. There is no single standardized annual capacity per production line, as effective output depends on antibody titer, culture cycle, batch frequency, bioreactor configuration, purification yield, and facility utilization. Large stainless-steel systems provide significant economies of scale for mature high-volume antibody products, whereas single-use systems offer greater flexibility for multiproduct and smaller-batch manufacturing.
Major cost components include culture media and single-use consumables, chromatography resins, facility depreciation, labor, quality testing, utilities, fill-finish operations, packaging, and cold-chain logistics. Unit manufacturing costs can decline materially as production scale and antibody titers increase, giving mature commercial products substantial economies of scale. Innovative originator biologics typically benefit from premium pricing and strong patent protection, and gross margins for mature products can generally reach approximately 60% to 85%. Biosimilars typically generate lower gross margins because of stronger price competition and distribution costs, although manufacturers with efficient large-scale production can still maintain attractive profitability.
The industry is characterized by high research and development, manufacturing, and regulatory barriers. Companies must not only complete complex clinical development and indication-specific validation but also establish biologics manufacturing systems that comply with good manufacturing practice requirements and consistently maintain product quality, aseptic control, and pharmacovigilance standards. For biosimilars, manufacturers must demonstrate a high degree of structural and functional similarity to the reference product and satisfy regulatory requirements concerning quality, clinical comparability, and immunogenicity. Companies with established cell culture, purification, and analytical quality platforms therefore possess significant competitive advantages.
The global competitive landscape remains relatively concentrated, with major originator products controlled by a limited number of large multinational pharmaceutical companies. These companies maintain their positions through extensive clinical evidence, indication expansion, brand recognition, and global commercialization networks. As patents for earlier products expire, mature molecules such as omalizumab are entering biosimilar competition, while biologics manufacturers from South Korea, China, and other regions are increasingly participating in the market. In China, the market remains in a stage of domestic substitution and increasing biologic penetration, with local companies initially targeting mature molecules such as omalizumab while expanding large-scale antibody manufacturing and commercialization capabilities.
Distribution and end-use patterns are highly specialized. Patients are commonly selected using serum immunoglobulin E levels, peripheral blood eosinophil counts, allergen testing, and other clinical indicators, making product use highly dependent on respiratory specialists, allergists, and other specialized physicians. As prefilled formulations, self-injection products, and remote patient-management models become more widely adopted, the proportion of home-based treatment is expected to increase. However, initial administration, response assessment, and monitoring for serious adverse events are expected to remain concentrated in professional healthcare settings.
Future industry growth will be driven primarily by higher penetration of biologic therapies in severe asthma, expansion into chronic obstructive pulmonary disease, development of novel inflammatory targets, biomarker-driven precision patient stratification, and improved patient access in emerging markets. At the same time, biosimilar competition for mature products such as omalizumab will continue to exert downward pressure on pricing, gradually shifting market growth from price-driven expansion toward growth in treated patient populations and new indications. Competition is therefore expected to move beyond efficacy at a single target toward a broader combination of patient coverage, lower dosing frequency, more convenient administration, long-term safety, and overall cost effectiveness.
Report Scope
This report studies the global Biologics for Obstructive Airway Diseases demand, key companies, and key regions.This report is a detailed and comprehensive analysis of the world market for Biologics for Obstructive Airway Diseases, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Biologics for Obstructive Airway Diseases that contribute to its increasing demand across many markets.
Highlights and key features of the study
- Global Biologics for Obstructive Airway Diseases total market, 2021-2032, (USD Million)
- Global Biologics for Obstructive Airway Diseases total market by region & country, CAGR, 2021-2032, (USD Million)
- U.S. VS China: Biologics for Obstructive Airway Diseases total market, key domestic companies, and share, (USD Million)
- Global Biologics for Obstructive Airway Diseases revenue by player, revenue and market share 2021-2026, (USD Million)
- Global Biologics for Obstructive Airway Diseases total market by Type, CAGR, 2021-2032, (USD Million)
- Global Biologics for Obstructive Airway Diseases total market by Application, CAGR, 2021-2032, (USD Million)
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Biologics for Obstructive Airway Diseases market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.Global Biologics for Obstructive Airway Diseases Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
Market Segmentation
Global Biologics for Obstructive Airway Diseases Market, Segmentation by Type:
- gE Targeting
- IL-5 Targeting
- IL-5 Receptor Targeting
- TSLP Targeting
- Other Targets
Global Biologics for Obstructive Airway Diseases Market, Segmentation by Therapeutic Application:
- Asthma
- Chronic Obstructive Pulmonary Disease
- Other Obstructive Airway Diseases
Global Biologics for Obstructive Airway Diseases Market, Segmentation by Product Status:
- Originator Biologics
- Biosimilars
Global Biologics for Obstructive Airway Diseases Market, Segmentation by Application:
- Hospitals
- Specialty Clinics
- Homecare Settings
- Other Healthcare Settings
Companies Profiled:
- Novartis AG
- Genentech, Inc. (Roche Group)
- GSK plc
- AstraZeneca plc
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Celltrion, Inc.
- Taizhou Mabtech Pharmaceutical Co., Ltd.
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
Key Questions Answered
1. How big is the global Biologics for Obstructive Airway Diseases market?2. What is the demand of the global Biologics for Obstructive Airway Diseases market?
3. What is the year over year growth of the global Biologics for Obstructive Airway Diseases market?
4. What is the total value of the global Biologics for Obstructive Airway Diseases market?
5. Who are the Major Players in the global Biologics for Obstructive Airway Diseases market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Biologics for Obstructive Airway Diseases Introduction
1.2 World Biologics for Obstructive Airway Diseases Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Biologics for Obstructive Airway Diseases Total Market by Region (by Headquarter Location)
1.3.1 World Biologics for Obstructive Airway Diseases Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.3.3 China Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.3.4 Europe Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.3.5 Japan Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.3.6 South Korea Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.3.7 ASEAN Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.3.8 India Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Biologics for Obstructive Airway Diseases Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.2 World Biologics for Obstructive Airway Diseases Consumption Value by Region
2.2.1 World Biologics for Obstructive Airway Diseases Consumption Value by Region (2021-2026)
2.2.2 World Biologics for Obstructive Airway Diseases Consumption Value Forecast by Region (2027-2032)
2.3 United States Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.4 China Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.5 Europe Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.6 Japan Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.7 South Korea Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.8 ASEAN Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.9 India Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
3 WORLD BIOLOGICS FOR OBSTRUCTIVE AIRWAY DISEASES COMPANIES COMPETITIVE ANALYSIS
3.1 World Biologics for Obstructive Airway Diseases Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Biologics for Obstructive Airway Diseases Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Biologics for Obstructive Airway Diseases in 2025
3.2.3 Global Concentration Ratios (CR8) for Biologics for Obstructive Airway Diseases in 2025
3.3 Biologics for Obstructive Airway Diseases Company Evaluation Quadrant
3.4 Biologics for Obstructive Airway Diseases Market: Overall Company Footprint Analysis
3.4.1 Biologics for Obstructive Airway Diseases Market: Region Footprint
3.4.2 Biologics for Obstructive Airway Diseases Market: Company Product Type Footprint
3.4.3 Biologics for Obstructive Airway Diseases Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Biologics for Obstructive Airway Diseases Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Biologics for Obstructive Airway Diseases Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Biologics for Obstructive Airway Diseases Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Biologics for Obstructive Airway Diseases Consumption Value Comparison
4.2.1 United States VS China: Biologics for Obstructive Airway Diseases Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Biologics for Obstructive Airway Diseases Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Biologics for Obstructive Airway Diseases Companies and Market Share, 2021-2026
4.3.1 United States Based Biologics for Obstructive Airway Diseases Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Biologics for Obstructive Airway Diseases Revenue, (2021-2026)
4.4 China Based Companies Biologics for Obstructive Airway Diseases Revenue and Market Share, 2021-2026
4.4.1 China Based Biologics for Obstructive Airway Diseases Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Biologics for Obstructive Airway Diseases Revenue, (2021-2026)
4.5 Rest of World Based Biologics for Obstructive Airway Diseases Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Biologics for Obstructive Airway Diseases Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Biologics for Obstructive Airway Diseases Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Biologics for Obstructive Airway Diseases Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 gE Targeting
5.2.2 IL-5 Targeting
5.2.3 IL-5 Receptor Targeting
5.2.4 TSLP Targeting
5.2.5 Other Targets
5.3 Market Segment by Type
5.3.1 World Biologics for Obstructive Airway Diseases Market Size by Type (2021-2026)
5.3.2 World Biologics for Obstructive Airway Diseases Market Size by Type (2027-2032)
5.3.3 World Biologics for Obstructive Airway Diseases Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY THERAPEUTIC APPLICATION
6.1 World Biologics for Obstructive Airway Diseases Market Size Overview by Therapeutic Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Therapeutic Application
6.2.1 Asthma
6.2.2 Chronic Obstructive Pulmonary Disease
6.2.3 Other Obstructive Airway Diseases
6.3 Market Segment by Therapeutic Application
6.3.1 World Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application (2021-2026)
6.3.2 World Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application (2027-2032)
6.3.3 World Biologics for Obstructive Airway Diseases Market Size Market Share by Therapeutic Application (2027-2032)
7 MARKET ANALYSIS BY PRODUCT STATUS
7.1 World Biologics for Obstructive Airway Diseases Market Size Overview by Product Status: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Product Status
7.2.1 Originator Biologics
7.2.2 Biosimilars
7.3 Market Segment by Product Status
7.3.1 World Biologics for Obstructive Airway Diseases Market Size by Product Status (2021-2026)
7.3.2 World Biologics for Obstructive Airway Diseases Market Size by Product Status (2027-2032)
7.3.3 World Biologics for Obstructive Airway Diseases Market Size Market Share by Product Status (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Biologics for Obstructive Airway Diseases Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospitals
8.2.2 Specialty Clinics
8.2.3 Homecare Settings
8.2.4 Other Healthcare Settings
8.3 Market Segment by Application
8.3.1 World Biologics for Obstructive Airway Diseases Market Size by Application (2021-2026)
8.3.2 World Biologics for Obstructive Airway Diseases Market Size by Application (2027-2032)
8.3.3 World Biologics for Obstructive Airway Diseases Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Novartis AG
9.1.1 Novartis AG Details
9.1.2 Novartis AG Major Business
9.1.3 Novartis AG Biologics for Obstructive Airway Diseases Product and Services
9.1.4 Novartis AG Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Novartis AG Recent Developments/Updates
9.1.6 Novartis AG Competitive Strengths & Weaknesses
9.2 Genentech, Inc. (Roche Group)
9.2.1 Genentech, Inc. (Roche Group) Details
9.2.2 Genentech, Inc. (Roche Group) Major Business
9.2.3 Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Product and Services
9.2.4 Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Genentech, Inc. (Roche Group) Recent Developments/Updates
9.2.6 Genentech, Inc. (Roche Group) Competitive Strengths & Weaknesses
9.3 GSK plc
9.3.1 GSK plc Details
9.3.2 GSK plc Major Business
9.3.3 GSK plc Biologics for Obstructive Airway Diseases Product and Services
9.3.4 GSK plc Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 GSK plc Recent Developments/Updates
9.3.6 GSK plc Competitive Strengths & Weaknesses
9.4 AstraZeneca plc
9.4.1 AstraZeneca plc Details
9.4.2 AstraZeneca plc Major Business
9.4.3 AstraZeneca plc Biologics for Obstructive Airway Diseases Product and Services
9.4.4 AstraZeneca plc Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 AstraZeneca plc Recent Developments/Updates
9.4.6 AstraZeneca plc Competitive Strengths & Weaknesses
9.5 Amgen Inc.
9.5.1 Amgen Inc. Details
9.5.2 Amgen Inc. Major Business
9.5.3 Amgen Inc. Biologics for Obstructive Airway Diseases Product and Services
9.5.4 Amgen Inc. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Amgen Inc. Recent Developments/Updates
9.5.6 Amgen Inc. Competitive Strengths & Weaknesses
9.6 Teva Pharmaceutical Industries Ltd.
9.6.1 Teva Pharmaceutical Industries Ltd. Details
9.6.2 Teva Pharmaceutical Industries Ltd. Major Business
9.6.3 Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Product and Services
9.6.4 Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
9.6.6 Teva Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
9.7 Celltrion, Inc.
9.7.1 Celltrion, Inc. Details
9.7.2 Celltrion, Inc. Major Business
9.7.3 Celltrion, Inc. Biologics for Obstructive Airway Diseases Product and Services
9.7.4 Celltrion, Inc. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Celltrion, Inc. Recent Developments/Updates
9.7.6 Celltrion, Inc. Competitive Strengths & Weaknesses
9.8 Taizhou Mabtech Pharmaceutical Co., Ltd.
9.8.1 Taizhou Mabtech Pharmaceutical Co., Ltd. Details
9.8.2 Taizhou Mabtech Pharmaceutical Co., Ltd. Major Business
9.8.3 Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Services
9.8.4 Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Taizhou Mabtech Pharmaceutical Co., Ltd. Recent Developments/Updates
9.8.6 Taizhou Mabtech Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.9 CSPC Megalith Biopharmaceutical Co., Ltd.
9.9.1 CSPC Megalith Biopharmaceutical Co., Ltd. Details
9.9.2 CSPC Megalith Biopharmaceutical Co., Ltd. Major Business
9.9.3 CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Services
9.9.4 CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 CSPC Megalith Biopharmaceutical Co., Ltd. Recent Developments/Updates
9.9.6 CSPC Megalith Biopharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.10 Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
9.10.1 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Details
9.10.2 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Major Business
9.10.3 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Product and Services
9.10.4 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Recent Developments/Updates
9.10.6 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Biologics for Obstructive Airway Diseases Industry Chain
10.2 Biologics for Obstructive Airway Diseases Upstream Analysis
10.3 Biologics for Obstructive Airway Diseases Midstream Analysis
10.4 Biologics for Obstructive Airway Diseases Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Biologics for Obstructive Airway Diseases Introduction
1.2 World Biologics for Obstructive Airway Diseases Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Biologics for Obstructive Airway Diseases Total Market by Region (by Headquarter Location)
1.3.1 World Biologics for Obstructive Airway Diseases Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.3.3 China Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.3.4 Europe Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.3.5 Japan Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.3.6 South Korea Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.3.7 ASEAN Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.3.8 India Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Biologics for Obstructive Airway Diseases Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.2 World Biologics for Obstructive Airway Diseases Consumption Value by Region
2.2.1 World Biologics for Obstructive Airway Diseases Consumption Value by Region (2021-2026)
2.2.2 World Biologics for Obstructive Airway Diseases Consumption Value Forecast by Region (2027-2032)
2.3 United States Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.4 China Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.5 Europe Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.6 Japan Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.7 South Korea Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.8 ASEAN Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
2.9 India Biologics for Obstructive Airway Diseases Consumption Value (2021-2032)
3 WORLD BIOLOGICS FOR OBSTRUCTIVE AIRWAY DISEASES COMPANIES COMPETITIVE ANALYSIS
3.1 World Biologics for Obstructive Airway Diseases Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Biologics for Obstructive Airway Diseases Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Biologics for Obstructive Airway Diseases in 2025
3.2.3 Global Concentration Ratios (CR8) for Biologics for Obstructive Airway Diseases in 2025
3.3 Biologics for Obstructive Airway Diseases Company Evaluation Quadrant
3.4 Biologics for Obstructive Airway Diseases Market: Overall Company Footprint Analysis
3.4.1 Biologics for Obstructive Airway Diseases Market: Region Footprint
3.4.2 Biologics for Obstructive Airway Diseases Market: Company Product Type Footprint
3.4.3 Biologics for Obstructive Airway Diseases Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Biologics for Obstructive Airway Diseases Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Biologics for Obstructive Airway Diseases Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Biologics for Obstructive Airway Diseases Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Biologics for Obstructive Airway Diseases Consumption Value Comparison
4.2.1 United States VS China: Biologics for Obstructive Airway Diseases Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Biologics for Obstructive Airway Diseases Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Biologics for Obstructive Airway Diseases Companies and Market Share, 2021-2026
4.3.1 United States Based Biologics for Obstructive Airway Diseases Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Biologics for Obstructive Airway Diseases Revenue, (2021-2026)
4.4 China Based Companies Biologics for Obstructive Airway Diseases Revenue and Market Share, 2021-2026
4.4.1 China Based Biologics for Obstructive Airway Diseases Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Biologics for Obstructive Airway Diseases Revenue, (2021-2026)
4.5 Rest of World Based Biologics for Obstructive Airway Diseases Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Biologics for Obstructive Airway Diseases Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Biologics for Obstructive Airway Diseases Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Biologics for Obstructive Airway Diseases Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 gE Targeting
5.2.2 IL-5 Targeting
5.2.3 IL-5 Receptor Targeting
5.2.4 TSLP Targeting
5.2.5 Other Targets
5.3 Market Segment by Type
5.3.1 World Biologics for Obstructive Airway Diseases Market Size by Type (2021-2026)
5.3.2 World Biologics for Obstructive Airway Diseases Market Size by Type (2027-2032)
5.3.3 World Biologics for Obstructive Airway Diseases Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY THERAPEUTIC APPLICATION
6.1 World Biologics for Obstructive Airway Diseases Market Size Overview by Therapeutic Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Therapeutic Application
6.2.1 Asthma
6.2.2 Chronic Obstructive Pulmonary Disease
6.2.3 Other Obstructive Airway Diseases
6.3 Market Segment by Therapeutic Application
6.3.1 World Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application (2021-2026)
6.3.2 World Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application (2027-2032)
6.3.3 World Biologics for Obstructive Airway Diseases Market Size Market Share by Therapeutic Application (2027-2032)
7 MARKET ANALYSIS BY PRODUCT STATUS
7.1 World Biologics for Obstructive Airway Diseases Market Size Overview by Product Status: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Product Status
7.2.1 Originator Biologics
7.2.2 Biosimilars
7.3 Market Segment by Product Status
7.3.1 World Biologics for Obstructive Airway Diseases Market Size by Product Status (2021-2026)
7.3.2 World Biologics for Obstructive Airway Diseases Market Size by Product Status (2027-2032)
7.3.3 World Biologics for Obstructive Airway Diseases Market Size Market Share by Product Status (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Biologics for Obstructive Airway Diseases Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospitals
8.2.2 Specialty Clinics
8.2.3 Homecare Settings
8.2.4 Other Healthcare Settings
8.3 Market Segment by Application
8.3.1 World Biologics for Obstructive Airway Diseases Market Size by Application (2021-2026)
8.3.2 World Biologics for Obstructive Airway Diseases Market Size by Application (2027-2032)
8.3.3 World Biologics for Obstructive Airway Diseases Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Novartis AG
9.1.1 Novartis AG Details
9.1.2 Novartis AG Major Business
9.1.3 Novartis AG Biologics for Obstructive Airway Diseases Product and Services
9.1.4 Novartis AG Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Novartis AG Recent Developments/Updates
9.1.6 Novartis AG Competitive Strengths & Weaknesses
9.2 Genentech, Inc. (Roche Group)
9.2.1 Genentech, Inc. (Roche Group) Details
9.2.2 Genentech, Inc. (Roche Group) Major Business
9.2.3 Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Product and Services
9.2.4 Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Genentech, Inc. (Roche Group) Recent Developments/Updates
9.2.6 Genentech, Inc. (Roche Group) Competitive Strengths & Weaknesses
9.3 GSK plc
9.3.1 GSK plc Details
9.3.2 GSK plc Major Business
9.3.3 GSK plc Biologics for Obstructive Airway Diseases Product and Services
9.3.4 GSK plc Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 GSK plc Recent Developments/Updates
9.3.6 GSK plc Competitive Strengths & Weaknesses
9.4 AstraZeneca plc
9.4.1 AstraZeneca plc Details
9.4.2 AstraZeneca plc Major Business
9.4.3 AstraZeneca plc Biologics for Obstructive Airway Diseases Product and Services
9.4.4 AstraZeneca plc Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 AstraZeneca plc Recent Developments/Updates
9.4.6 AstraZeneca plc Competitive Strengths & Weaknesses
9.5 Amgen Inc.
9.5.1 Amgen Inc. Details
9.5.2 Amgen Inc. Major Business
9.5.3 Amgen Inc. Biologics for Obstructive Airway Diseases Product and Services
9.5.4 Amgen Inc. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Amgen Inc. Recent Developments/Updates
9.5.6 Amgen Inc. Competitive Strengths & Weaknesses
9.6 Teva Pharmaceutical Industries Ltd.
9.6.1 Teva Pharmaceutical Industries Ltd. Details
9.6.2 Teva Pharmaceutical Industries Ltd. Major Business
9.6.3 Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Product and Services
9.6.4 Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
9.6.6 Teva Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
9.7 Celltrion, Inc.
9.7.1 Celltrion, Inc. Details
9.7.2 Celltrion, Inc. Major Business
9.7.3 Celltrion, Inc. Biologics for Obstructive Airway Diseases Product and Services
9.7.4 Celltrion, Inc. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Celltrion, Inc. Recent Developments/Updates
9.7.6 Celltrion, Inc. Competitive Strengths & Weaknesses
9.8 Taizhou Mabtech Pharmaceutical Co., Ltd.
9.8.1 Taizhou Mabtech Pharmaceutical Co., Ltd. Details
9.8.2 Taizhou Mabtech Pharmaceutical Co., Ltd. Major Business
9.8.3 Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Services
9.8.4 Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Taizhou Mabtech Pharmaceutical Co., Ltd. Recent Developments/Updates
9.8.6 Taizhou Mabtech Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.9 CSPC Megalith Biopharmaceutical Co., Ltd.
9.9.1 CSPC Megalith Biopharmaceutical Co., Ltd. Details
9.9.2 CSPC Megalith Biopharmaceutical Co., Ltd. Major Business
9.9.3 CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Services
9.9.4 CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 CSPC Megalith Biopharmaceutical Co., Ltd. Recent Developments/Updates
9.9.6 CSPC Megalith Biopharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.10 Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
9.10.1 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Details
9.10.2 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Major Business
9.10.3 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Product and Services
9.10.4 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Recent Developments/Updates
9.10.6 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Biologics for Obstructive Airway Diseases Industry Chain
10.2 Biologics for Obstructive Airway Diseases Upstream Analysis
10.3 Biologics for Obstructive Airway Diseases Midstream Analysis
10.4 Biologics for Obstructive Airway Diseases Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Biologics for Obstructive Airway Diseases Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Biologics for Obstructive Airway Diseases Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Biologics for Obstructive Airway Diseases Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Biologics for Obstructive Airway Diseases Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Biologics for Obstructive Airway Diseases Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Biologics for Obstructive Airway Diseases Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Biologics for Obstructive Airway Diseases Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Biologics for Obstructive Airway Diseases Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Biologics for Obstructive Airway Diseases Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Biologics for Obstructive Airway Diseases Players in 2025
Table 12. World Biologics for Obstructive Airway Diseases Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Biologics for Obstructive Airway Diseases Company Evaluation Quadrant
Table 14. Head Office of Key Biologics for Obstructive Airway Diseases Players
Table 15. Biologics for Obstructive Airway Diseases Market: Company Product Type Footprint
Table 16. Biologics for Obstructive Airway Diseases Market: Company Product Application Footprint
Table 17. Biologics for Obstructive Airway Diseases Mergers & Acquisitions Activity
Table 18. United States VS China Biologics for Obstructive Airway Diseases Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Biologics for Obstructive Airway Diseases Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Biologics for Obstructive Airway Diseases Companies, Headquarters (States, Country)
Table 21. United States Based Companies Biologics for Obstructive Airway Diseases Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Biologics for Obstructive Airway Diseases Revenue Market Share (2021-2026)
Table 23. China Based Biologics for Obstructive Airway Diseases Companies, Headquarters (Province, Country)
Table 24. China Based Companies Biologics for Obstructive Airway Diseases Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Biologics for Obstructive Airway Diseases Revenue Market Share (2021-2026)
Table 26. Rest of World Based Biologics for Obstructive Airway Diseases Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Biologics for Obstructive Airway Diseases Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Biologics for Obstructive Airway Diseases Revenue Market Share (2021-2026)
Table 29. World Biologics for Obstructive Airway Diseases Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Biologics for Obstructive Airway Diseases Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Biologics for Obstructive Airway Diseases Market Size by Type (2027-2032) & (USD Million)
Table 32. World Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application, (USD Million), 2021 & 2025 & 2032
Table 33. World Biologics for Obstructive Airway Diseases Market Size Value by Therapeutic Application (2021-2026) & (USD Million)
Table 34. World Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application (2027-2032) & (USD Million)
Table 35. World Biologics for Obstructive Airway Diseases Market Size by Product Status, (USD Million), 2021 & 2025 & 2032
Table 36. World Biologics for Obstructive Airway Diseases Market Size Value by Product Status (2021-2026) & (USD Million)
Table 37. World Biologics for Obstructive Airway Diseases Market Size by Product Status (2027-2032) & (USD Million)
Table 38. World Biologics for Obstructive Airway Diseases Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Biologics for Obstructive Airway Diseases Market Size by Application (2021-2026) & (USD Million)
Table 40. World Biologics for Obstructive Airway Diseases Market Size by Application (2027-2032) & (USD Million)
Table 41. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 42. Novartis AG Major Business
Table 43. Novartis AG Biologics for Obstructive Airway Diseases Product and Services
Table 44. Novartis AG Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Novartis AG Recent Developments/Updates
Table 46. Novartis AG Competitive Strengths & Weaknesses
Table 47. Genentech, Inc. (Roche Group) Basic Information, Manufacturing Base and Competitors
Table 48. Genentech, Inc. (Roche Group) Major Business
Table 49. Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Product and Services
Table 50. Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Genentech, Inc. (Roche Group) Recent Developments/Updates
Table 52. Genentech, Inc. (Roche Group) Competitive Strengths & Weaknesses
Table 53. GSK plc Basic Information, Manufacturing Base and Competitors
Table 54. GSK plc Major Business
Table 55. GSK plc Biologics for Obstructive Airway Diseases Product and Services
Table 56. GSK plc Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. GSK plc Recent Developments/Updates
Table 58. GSK plc Competitive Strengths & Weaknesses
Table 59. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 60. AstraZeneca plc Major Business
Table 61. AstraZeneca plc Biologics for Obstructive Airway Diseases Product and Services
Table 62. AstraZeneca plc Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. AstraZeneca plc Recent Developments/Updates
Table 64. AstraZeneca plc Competitive Strengths & Weaknesses
Table 65. Amgen Inc. Basic Information, Manufacturing Base and Competitors
Table 66. Amgen Inc. Major Business
Table 67. Amgen Inc. Biologics for Obstructive Airway Diseases Product and Services
Table 68. Amgen Inc. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Amgen Inc. Recent Developments/Updates
Table 70. Amgen Inc. Competitive Strengths & Weaknesses
Table 71. Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
Table 72. Teva Pharmaceutical Industries Ltd. Major Business
Table 73. Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Product and Services
Table 74. Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 76. Teva Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
Table 77. Celltrion, Inc. Basic Information, Manufacturing Base and Competitors
Table 78. Celltrion, Inc. Major Business
Table 79. Celltrion, Inc. Biologics for Obstructive Airway Diseases Product and Services
Table 80. Celltrion, Inc. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Celltrion, Inc. Recent Developments/Updates
Table 82. Celltrion, Inc. Competitive Strengths & Weaknesses
Table 83. Taizhou Mabtech Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 84. Taizhou Mabtech Pharmaceutical Co., Ltd. Major Business
Table 85. Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Services
Table 86. Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Taizhou Mabtech Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 88. Taizhou Mabtech Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 89. CSPC Megalith Biopharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 90. CSPC Megalith Biopharmaceutical Co., Ltd. Major Business
Table 91. CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Services
Table 92. CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. CSPC Megalith Biopharmaceutical Co., Ltd. Recent Developments/Updates
Table 94. CSPC Megalith Biopharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 95. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 96. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Major Business
Table 97. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Product and Services
Table 98. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Recent Developments/Updates
Table 100. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Competitive Strengths & Weaknesses
Table 101. Global Key Players of Biologics for Obstructive Airway Diseases Upstream (Raw Materials)
Table 102. Global Biologics for Obstructive Airway Diseases Typical Customers
Table 1. World Biologics for Obstructive Airway Diseases Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Biologics for Obstructive Airway Diseases Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Biologics for Obstructive Airway Diseases Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Biologics for Obstructive Airway Diseases Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Biologics for Obstructive Airway Diseases Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Biologics for Obstructive Airway Diseases Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Biologics for Obstructive Airway Diseases Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Biologics for Obstructive Airway Diseases Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Biologics for Obstructive Airway Diseases Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Biologics for Obstructive Airway Diseases Players in 2025
Table 12. World Biologics for Obstructive Airway Diseases Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Biologics for Obstructive Airway Diseases Company Evaluation Quadrant
Table 14. Head Office of Key Biologics for Obstructive Airway Diseases Players
Table 15. Biologics for Obstructive Airway Diseases Market: Company Product Type Footprint
Table 16. Biologics for Obstructive Airway Diseases Market: Company Product Application Footprint
Table 17. Biologics for Obstructive Airway Diseases Mergers & Acquisitions Activity
Table 18. United States VS China Biologics for Obstructive Airway Diseases Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Biologics for Obstructive Airway Diseases Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Biologics for Obstructive Airway Diseases Companies, Headquarters (States, Country)
Table 21. United States Based Companies Biologics for Obstructive Airway Diseases Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Biologics for Obstructive Airway Diseases Revenue Market Share (2021-2026)
Table 23. China Based Biologics for Obstructive Airway Diseases Companies, Headquarters (Province, Country)
Table 24. China Based Companies Biologics for Obstructive Airway Diseases Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Biologics for Obstructive Airway Diseases Revenue Market Share (2021-2026)
Table 26. Rest of World Based Biologics for Obstructive Airway Diseases Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Biologics for Obstructive Airway Diseases Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Biologics for Obstructive Airway Diseases Revenue Market Share (2021-2026)
Table 29. World Biologics for Obstructive Airway Diseases Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Biologics for Obstructive Airway Diseases Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Biologics for Obstructive Airway Diseases Market Size by Type (2027-2032) & (USD Million)
Table 32. World Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application, (USD Million), 2021 & 2025 & 2032
Table 33. World Biologics for Obstructive Airway Diseases Market Size Value by Therapeutic Application (2021-2026) & (USD Million)
Table 34. World Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application (2027-2032) & (USD Million)
Table 35. World Biologics for Obstructive Airway Diseases Market Size by Product Status, (USD Million), 2021 & 2025 & 2032
Table 36. World Biologics for Obstructive Airway Diseases Market Size Value by Product Status (2021-2026) & (USD Million)
Table 37. World Biologics for Obstructive Airway Diseases Market Size by Product Status (2027-2032) & (USD Million)
Table 38. World Biologics for Obstructive Airway Diseases Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Biologics for Obstructive Airway Diseases Market Size by Application (2021-2026) & (USD Million)
Table 40. World Biologics for Obstructive Airway Diseases Market Size by Application (2027-2032) & (USD Million)
Table 41. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 42. Novartis AG Major Business
Table 43. Novartis AG Biologics for Obstructive Airway Diseases Product and Services
Table 44. Novartis AG Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Novartis AG Recent Developments/Updates
Table 46. Novartis AG Competitive Strengths & Weaknesses
Table 47. Genentech, Inc. (Roche Group) Basic Information, Manufacturing Base and Competitors
Table 48. Genentech, Inc. (Roche Group) Major Business
Table 49. Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Product and Services
Table 50. Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Genentech, Inc. (Roche Group) Recent Developments/Updates
Table 52. Genentech, Inc. (Roche Group) Competitive Strengths & Weaknesses
Table 53. GSK plc Basic Information, Manufacturing Base and Competitors
Table 54. GSK plc Major Business
Table 55. GSK plc Biologics for Obstructive Airway Diseases Product and Services
Table 56. GSK plc Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. GSK plc Recent Developments/Updates
Table 58. GSK plc Competitive Strengths & Weaknesses
Table 59. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 60. AstraZeneca plc Major Business
Table 61. AstraZeneca plc Biologics for Obstructive Airway Diseases Product and Services
Table 62. AstraZeneca plc Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. AstraZeneca plc Recent Developments/Updates
Table 64. AstraZeneca plc Competitive Strengths & Weaknesses
Table 65. Amgen Inc. Basic Information, Manufacturing Base and Competitors
Table 66. Amgen Inc. Major Business
Table 67. Amgen Inc. Biologics for Obstructive Airway Diseases Product and Services
Table 68. Amgen Inc. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Amgen Inc. Recent Developments/Updates
Table 70. Amgen Inc. Competitive Strengths & Weaknesses
Table 71. Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
Table 72. Teva Pharmaceutical Industries Ltd. Major Business
Table 73. Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Product and Services
Table 74. Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 76. Teva Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
Table 77. Celltrion, Inc. Basic Information, Manufacturing Base and Competitors
Table 78. Celltrion, Inc. Major Business
Table 79. Celltrion, Inc. Biologics for Obstructive Airway Diseases Product and Services
Table 80. Celltrion, Inc. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Celltrion, Inc. Recent Developments/Updates
Table 82. Celltrion, Inc. Competitive Strengths & Weaknesses
Table 83. Taizhou Mabtech Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 84. Taizhou Mabtech Pharmaceutical Co., Ltd. Major Business
Table 85. Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Services
Table 86. Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Taizhou Mabtech Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 88. Taizhou Mabtech Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 89. CSPC Megalith Biopharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 90. CSPC Megalith Biopharmaceutical Co., Ltd. Major Business
Table 91. CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Services
Table 92. CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. CSPC Megalith Biopharmaceutical Co., Ltd. Recent Developments/Updates
Table 94. CSPC Megalith Biopharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 95. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 96. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Major Business
Table 97. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Product and Services
Table 98. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Recent Developments/Updates
Table 100. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Competitive Strengths & Weaknesses
Table 101. Global Key Players of Biologics for Obstructive Airway Diseases Upstream (Raw Materials)
Table 102. Global Biologics for Obstructive Airway Diseases Typical Customers
LIST OF FIGURES
Figure 1. Biologics for Obstructive Airway Diseases Picture
Figure 2. World Biologics for Obstructive Airway Diseases Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Biologics for Obstructive Airway Diseases Total Revenue (2021-2032) & (USD Million)
Figure 4. World Biologics for Obstructive Airway Diseases Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Biologics for Obstructive Airway Diseases Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 13. Biologics for Obstructive Airway Diseases Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 16. World Biologics for Obstructive Airway Diseases Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 18. China Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 23. India Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Biologics for Obstructive Airway Diseases by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Biologics for Obstructive Airway Diseases Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Biologics for Obstructive Airway Diseases Markets in 2025
Figure 27. United States VS China: Biologics for Obstructive Airway Diseases Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Biologics for Obstructive Airway Diseases Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Biologics for Obstructive Airway Diseases Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Biologics for Obstructive Airway Diseases Market Size Market Share by Type in 2025
Figure 31. gE Targeting
Figure 32. IL-5 Targeting
Figure 33. IL-5 Receptor Targeting
Figure 34. TSLP Targeting
Figure 35. Other Targets
Figure 36. World Biologics for Obstructive Airway Diseases Market Size Market Share by Type (2021-2032)
Figure 37. World Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application, (USD Million), 2021 & 2025 & 2032
Figure 38. World Biologics for Obstructive Airway Diseases Market Size Market Share by Therapeutic Application in 2025
Figure 39. Asthma
Figure 40. Chronic Obstructive Pulmonary Disease
Figure 41. Other Obstructive Airway Diseases
Figure 42. World Biologics for Obstructive Airway Diseases Market Size Market Share by Therapeutic Application (2021-2032)
Figure 43. World Biologics for Obstructive Airway Diseases Market Size by Product Status, (USD Million), 2021 & 2025 & 2032
Figure 44. World Biologics for Obstructive Airway Diseases Market Size Market Share by Product Status in 2025
Figure 45. Originator Biologics
Figure 46. Biosimilars
Figure 47. World Biologics for Obstructive Airway Diseases Market Size Market Share by Product Status (2021-2032)
Figure 48. World Biologics for Obstructive Airway Diseases Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 49. World Biologics for Obstructive Airway Diseases Market Size Market Share by Application in 2025
Figure 50. Hospitals
Figure 51. Specialty Clinics
Figure 52. Homecare Settings
Figure 53. Other Healthcare Settings
Figure 54. World Biologics for Obstructive Airway Diseases Market Size Market Share by Application (2021-2032)
Figure 55. Biologics for Obstructive Airway Diseases Industrial Chain
Figure 56. Methodology
Figure 57. Research Process and Data Source
Figure 1. Biologics for Obstructive Airway Diseases Picture
Figure 2. World Biologics for Obstructive Airway Diseases Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Biologics for Obstructive Airway Diseases Total Revenue (2021-2032) & (USD Million)
Figure 4. World Biologics for Obstructive Airway Diseases Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Biologics for Obstructive Airway Diseases Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Biologics for Obstructive Airway Diseases Revenue (2021-2032) & (USD Million)
Figure 13. Biologics for Obstructive Airway Diseases Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 16. World Biologics for Obstructive Airway Diseases Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 18. China Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 23. India Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Biologics for Obstructive Airway Diseases by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Biologics for Obstructive Airway Diseases Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Biologics for Obstructive Airway Diseases Markets in 2025
Figure 27. United States VS China: Biologics for Obstructive Airway Diseases Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Biologics for Obstructive Airway Diseases Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Biologics for Obstructive Airway Diseases Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Biologics for Obstructive Airway Diseases Market Size Market Share by Type in 2025
Figure 31. gE Targeting
Figure 32. IL-5 Targeting
Figure 33. IL-5 Receptor Targeting
Figure 34. TSLP Targeting
Figure 35. Other Targets
Figure 36. World Biologics for Obstructive Airway Diseases Market Size Market Share by Type (2021-2032)
Figure 37. World Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application, (USD Million), 2021 & 2025 & 2032
Figure 38. World Biologics for Obstructive Airway Diseases Market Size Market Share by Therapeutic Application in 2025
Figure 39. Asthma
Figure 40. Chronic Obstructive Pulmonary Disease
Figure 41. Other Obstructive Airway Diseases
Figure 42. World Biologics for Obstructive Airway Diseases Market Size Market Share by Therapeutic Application (2021-2032)
Figure 43. World Biologics for Obstructive Airway Diseases Market Size by Product Status, (USD Million), 2021 & 2025 & 2032
Figure 44. World Biologics for Obstructive Airway Diseases Market Size Market Share by Product Status in 2025
Figure 45. Originator Biologics
Figure 46. Biosimilars
Figure 47. World Biologics for Obstructive Airway Diseases Market Size Market Share by Product Status (2021-2032)
Figure 48. World Biologics for Obstructive Airway Diseases Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 49. World Biologics for Obstructive Airway Diseases Market Size Market Share by Application in 2025
Figure 50. Hospitals
Figure 51. Specialty Clinics
Figure 52. Homecare Settings
Figure 53. Other Healthcare Settings
Figure 54. World Biologics for Obstructive Airway Diseases Market Size Market Share by Application (2021-2032)
Figure 55. Biologics for Obstructive Airway Diseases Industrial Chain
Figure 56. Methodology
Figure 57. Research Process and Data Source
